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Cigarette smoking, which exposes the lung to high
concentrations of reactive oxygen species (ROS), is
the major risk factor for chronic obstructive pul-
monary disease (COPD) [1]. ROS are responsible
for lipid peroxidation, protein oxidation, DNA alter-
ations, and cell damage. Coupled with oxidant/
antioxidant imbalance, these changes lead to lung
inflammatory responses through multiple pathways,
among which the activation of stress kinases (c-Jun
activated kinase, extracellular signal-regulated ki-
nase, p38 kinase) and redox-sensitive transcription
factors, such as nuclear factor (NF)-kappaB and ac-
tivator protein-1, resulting in the expression of ki-
nase- and NF-κB-dependent proinflammatory cy-
tokines and chemokines [2]. 
COPD is related to smoking habit in the majority of
cases, and smoking cessation is the single most
beneficial and effective way to reduce COPD mor-
bidity, hospital admissions and disease progression
[1]. However, persistent inflammation in the air-
ways of COPD subjects may continue after smoking
cessation, as shown by studies showing a similar
number of airway inflammatory cells, including
CD4+ and CD8+ lymphocytes, in the bronchial
biopsies of both current smokers and ex-smokers
with COPD [3], and by other studies analyzing the
composition of induced sputum, which showed a
persistent increase in the number of airway neu-
trophils and lymphocytes one year after smoking
cessation [4]. A persistent overall burden of non in-
vasive markers of oxidative stress has also been
found in the airways after smoking cessation [5].
Also systemic markers of inflammation were found
elevated in the serum of COPD patients [6,7]. Taken
together, these studies indicate that, in COPD pa-
tients, ongoing inflammation is persistent in spite of
smoking cessation: this phenomenon is considered
one of the determinants of the progressive decline
in lung function.
This issue of Multidisciplinary Respiratory Medicine
features an article by Serapinas et al. [8] on the
presence of markers of systemic inflammation in a
sample of 320 COPD patients according to their
smoking status. The authors devoted their attention
to the serum concentrations of the following set of
oxidant markers: C-reactive protein (CRP), alpha-1
antitrypsin (AAT), tumor necrosis factor-α (TNF-α),
and soluble tumor necrosis factor receptor (sTNFR)-
1 and sTNFR-2. The markers were analyzed in rela-
tion to current smoking (n = 202) and ex-smoking (n
= 61), as well never-smoker (n = 57) status. Mean
(SD) forced expiratory volume in one second/
forced vital capacity (FEV1/FVC) (%) was 54.8
(10.7), while mean (SD) pack/years in smokers and
ex-smokers was 22.7 ± 12.9. The main result of the
study was that AAT, CRP and sTNFR-1 concentra-
tions were significantly increased in both smokers
and ex-smokers as compared to never-smokers. 
This study adds to the number of reports showing
the presence of systemic and airway inflammation
in COPD patients, irrespective of whether they
were current or ex-smokers. Although inflammation
is also present as a consequence of smoking in the
airways of asymptomatic smokers, a significant de-
crease of oxidant markers occurs after smoking ces-
sation in these subjects [4]. It is not known why - at
variance with what occurs in asymptomatic smok-
ers - inflammation persists after quitting smoking in
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COPD patients [1]. 
One of the leading explanations is the altered regu-
lation of inflammatory gene expression, even
though epigenetic mechanisms are implicated too.
In a recent study it has been shown that smoking
per se modulates the expression of genes from all
the inflammatory functional groups except for the
matrix metalloproteinases group [10]. The inflam-
mation related genes (except TNF-a) were found to
be up-regulated, while genes from the growth fac-
tor/receptor group, adhesion molecules and vessel
tone/maintenance factors were down-regulated in
smokers. 
It is notable that all of these genes exhibited a sim-
ilar profile in patients with moderate COPD, sug-
gesting a crucial role of cigarette smoking in the gen-
esis of these changes. However, one of the most sig-
nificant changes associated with COPD was the in-
creased expression of matrix metalloproteinases [10].
Although the COPD puzzle is still far from being
solved, multidisciplinary research linking the differ-
ent expertise of epidemiological, biological, trans-
lational and clinical nature is believed to be the
best response to such a difficult task.
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